These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23618682)

  • 1. Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
    Bennett D; Yan B
    J Clin Neurosci; 2013 Jun; 20(6):767-70. PubMed ID: 23618682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
    Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of clopidogrel: evidence and perspectives.
    Yin T; Miyata T
    Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
    Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
    Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress of antiplatelet pharmacogenomics.
    Oestreich JH
    Curr Drug Targets; 2011 Nov; 12(12):1848-58. PubMed ID: 21718233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel and genetic testing: is it necessary for everyone?
    Goswami S; Cheng-Lai A; Nawarskas J
    Cardiol Rev; 2012; 20(2):96-100. PubMed ID: 22293861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the CYP 2C19*2 polymorphism on stroke care.
    Nyírő G; Inczédy-Farkas G; Reményi V; Gál A; Pál Z; Molnár MJ
    Acta Physiol Hung; 2012 Mar; 99(1):33-9. PubMed ID: 22425806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
    Jin B; Ni HC; Shen W; Li J; Shi HM; Li Y
    Mol Biol Rep; 2011 Mar; 38(3):1697-702. PubMed ID: 20845077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.